This is BrainsWay’s global website. The website includes information on clinical indications that were not cleared by the FDA and are considered investigational by the U.S. medical device regulations. BrainsWay D treatment is FDA cleared for patients with MDD who failed to respond to one or more anti-depressants in the current episode.
Patients diagnosed with Alzheimer disease (AD) showsevere cognitive deficits. Decline in memory, language, and executivefunction have repeatedly been reported. Although AD affects 60% to80% of demented elderly patients, there is currently no cure and limitedtreatment alternatives.
The aim of the study was to evaluate the feasibility of stimulating prefrontal cortex (PFC) with deep transcranial magnetic stimulation (dTMS) to ameliorate cognitive deficits in patients suffering from AD.
Eleven patients (6 males; mean [SD] age, 76  years) in moderate to severe stages of AD received dTMS over the PFC for 20 sessions. Computerized battery (Mindstreams [MS]) and neuropsychological testing (Addenbrooke Cognitive Examination [ACE]) were usedto assess cognitive performance before and after treatment.
Compared with baseline, 60% of patients performed better on the MS battery and 77% of patients performed better on the ACE testing at the end of dTMS treatment. None of the patients performed worse on both tests at the end of treatment. The DTMS effects on the group mean in ACE and MS approached significance (p=0.065 and p=0.086, respectively). A dTMS-induced improvement in the ACE was significant (p=0.001) on patients in more progressed stage (n = 6). Change in ACE negatively correlated with score at baseline.
In sum, the current report of this novel technique indicates that deep stimulation might lead to preservation and even improvement of cognitive functions, at least during the time of treatment. Further examinations should report of long-term effects of this technique.